HER2 Inhibitor Response Markers
HER2 inhibitor sensitivity: HER2 protein and gene amplification
Ray-Coquard, I., J.P. Guastalla, et al. (2009). HER2 Overexpression/Amplification and Trastuzumab Treatment in Advanced Ovarian Cancer: A GINECO Phase II Study. Clin Ovarian Cancer 2:17-22.
Seidman, A. D., M. N. Fornier, et al. (2001). Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19: 2587-95.
Di Leo, A., Gomez, H.L., Aziz, Z., Zvirbule, Z., Bines, J., Arbushites, M.C., Guerrera, S.F., Koehler, M., Oliva, C., Stein, S.H., et al. (2008). Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 26: 5544-5552.
HER2 inhibitor resistance: PIK3CA
Wang, L., Zhang, Q., Zhang, J., Sun, S., Guo, H., Jia, Z., Wang, B., Shao, Z., Wang, Z., and Hu, X. (2011). PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer 11: 248.
Chandarlapaty, S., Sakr, R.A., Giri, D., Patil, S., Heguy, A., Morrow, M., Modi, S., Norton, L., Rosen, N., Hudis, C., et al. (2012). Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast Cancer. Clin Cancer Res 18: 6784-6791.
Jensen, J.D., Knoop, A., Laenkholm, A.V., Grauslund, M., Jensen, M.B., Santoni-Rugiu, E., Andersson, M., and Ewertz, M. (2012). PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. Ann Oncol 23: 2034-2042.
HER2 inhibitor resistance: PTEN
Dave, B., Migliaccio, I., Gutierrez, M.C., Wu, M.F., Chamness, G.C., Wong, H., Narasanna, A., Chakrabarty, A., Hilsenbeck, S.G., Huang, J., et al. (2011). Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol 29: 166-173.
Wang, L., Zhang, Q., Zhang, J., Sun, S., Guo, H., Jia, Z., Wang, B., Shao, Z., Wang, Z., and Hu, X. (2011). PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer 11: 248.
Jensen, J.D., Knoop, A., Laenkholm, A.V., Grauslund, M., Jensen, M.B., Santoni-Rugiu, E., Andersson, M., and Ewertz, M. (2012). PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. Ann Oncol 23: 2034-2042.
Chandarlapaty, S., Sakr, R.A., Giri, D., Patil, S., Heguy, A., Morrow, M., Modi, S., Norton, L., Rosen, N., Hudis, C., et al. (2012). Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast Cancer. Clin Cancer Res 18: 6784-6791.